Market Cap 4.96B
Revenue (ttm) 1.56B
Net Income (ttm) 367.07M
EPS (ttm) N/A
PE Ratio 14.26
Forward PE 20.62
Profit Margin 23.57%
Debt to Equity Ratio 0.00
Volume 2,079,600
Avg Vol 2,027,630
Day's Range N/A - N/A
Shares Out 165.08M
Stochastic %K 9%
Beta 0.54
Analysts Strong Sell
Price Target $42.12

Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 772 8000
Address:
Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland
LarryYMB
LarryYMB Oct. 24 at 5:01 PM
$ALKS jumped here, better close the deal on avadel on time and maximize the asset, time to kill jazz and steal the entire narcolepsy market!
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 4:27 PM
Piper Sandler has updated their rating for Alkermes ( $ALKS ) to Overweight with a price target of 45.
1 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:12 PM
$ALKS makes a bold $2.1B move into sleep disorders 😴 The acquisition of Avadel brings Lumryz into Alkermes’ portfolio — unlocking a new growth avenue beyond its current focus areas. Discover what this deal could mean for Alkermes’ long-term story 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-teaser-17320&ADID=SYND_STOCKTWITS_TWEET_2_2775426_TEASER_17320
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:12 PM
$ALKS to acquire $AVDL in a $2.1B deal — is this a game-changer for ALKS? 🚀 🔹 38% premium to AVDL's 3-month average price 🔹 Lumryz sales up nearly 76% in the first six months of 2025, poised for robust growth 🔹 Strategic entry into the sleep medicine market Discover what this acquisition means for Alkermes' future 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-body-17298&ADID=SYND_STOCKTWITS_TWEET_2_2775426_BODY_17298
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:23 PM
RBC Capital updates rating for Alkermes ( $ALKS ) to Outperform, target set at 45 → 47.
0 · Reply
Jp2Easy
Jp2Easy Oct. 22 at 7:27 PM
$ALKS Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz.
0 · Reply
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
NebulaKnight65
NebulaKnight65 Oct. 22 at 1:03 PM
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 22 at 12:50 PM
$AVDL (+3.7% pre) Avadel settles with $JAZZ Jazz Pharma; agrees to be acquired by $ALKS Alkermes https://ooc.bz/l/81384
0 · Reply
notreload_ai
notreload_ai Oct. 22 at 12:07 PM
$ALKS , $AVDL ... Alkermes announces $2.1B acquisition of Avadel Pharmaceuticals to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026. https://notreload.xyz/alkermes-acquires-avadel-sleep-drug-deal/
0 · Reply
Latest News on ALKS
Alkermes plc (ALKS) M&A Call Transcript

Oct 22, 2025, 10:53 AM EDT - 2 days ago

Alkermes plc (ALKS) M&A Call Transcript


Alkermes to acquire Avadel for up to $2.1 billion

Oct 22, 2025, 7:11 AM EDT - 3 days ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL


Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 12, 2025, 9:00 AM EDT - 6 weeks ago

Alkermes Appoints Joshua Reed as Chief Financial Officer


Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Sep 8, 2025, 2:34 PM EDT - 6 weeks ago

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)


Alkermes: A More Than Solid Quarter

Jul 30, 2025, 5:08 PM EDT - 3 months ago

Alkermes: A More Than Solid Quarter


Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 2:47 PM EDT - 3 months ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript


Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results


Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:21 AM EDT - 6 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript


Alkermes plc Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 6 months ago

Alkermes plc Reports First Quarter 2025 Financial Results


Alkermes to Participate in Upcoming Investor Conferences

Feb 26, 2025, 4:00 PM EST - 8 months ago

Alkermes to Participate in Upcoming Investor Conferences


Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 2:40 PM EST - 9 months ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript


Alkermes to Participate in Two Upcoming Investor Conferences

Nov 11, 2024, 4:00 PM EST - 1 year ago

Alkermes to Participate in Two Upcoming Investor Conferences


Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:04 PM EDT - 1 year ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript


Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Third Quarter 2024 Financial Results


Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 2:20 PM EDT - 1 year ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript


Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Second Quarter 2024 Financial Results


The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17, 2024, 8:27 AM EDT - 1 year ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety


LarryYMB
LarryYMB Oct. 24 at 5:01 PM
$ALKS jumped here, better close the deal on avadel on time and maximize the asset, time to kill jazz and steal the entire narcolepsy market!
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 4:27 PM
Piper Sandler has updated their rating for Alkermes ( $ALKS ) to Overweight with a price target of 45.
1 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 4:12 PM
$ALKS makes a bold $2.1B move into sleep disorders 😴 The acquisition of Avadel brings Lumryz into Alkermes’ portfolio — unlocking a new growth avenue beyond its current focus areas. Discover what this deal could mean for Alkermes’ long-term story 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-teaser-17320&ADID=SYND_STOCKTWITS_TWEET_2_2775426_TEASER_17320
0 · Reply
ZacksResearch
ZacksResearch Oct. 23 at 3:12 PM
$ALKS to acquire $AVDL in a $2.1B deal — is this a game-changer for ALKS? 🚀 🔹 38% premium to AVDL's 3-month average price 🔹 Lumryz sales up nearly 76% in the first six months of 2025, poised for robust growth 🔹 Strategic entry into the sleep medicine market Discover what this acquisition means for Alkermes' future 👉 https://www.zacks.com/stock/news/2775426/alks-to-enter-sleep-disorder-market-with-21b-avadel-acquisition?cid=sm-stocktwits-2-2775426-body-17298&ADID=SYND_STOCKTWITS_TWEET_2_2775426_BODY_17298
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:23 PM
RBC Capital updates rating for Alkermes ( $ALKS ) to Outperform, target set at 45 → 47.
0 · Reply
Jp2Easy
Jp2Easy Oct. 22 at 7:27 PM
$ALKS Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz.
0 · Reply
Quantumup
Quantumup Oct. 22 at 7:09 PM
RBC Capital⬆️ $ALKS's PT to $ 47 from $45, reiterated at Outperform, and said, Following the announcement of ALKS's intention to acquire $AVDL, we had the chance to catch up with ALKS mgmt. $JAZZ $CNTA $AXSM RBC Capital added: We think the acquisition checks multiple boxes — supporting a key future growth driver with a commercial base of operations, bringing in near-term revenues, and not stretching the balance sheet — and we think bringing in AVDL should strengthen both the near- and mid-term outlook for ALKS. We continue to like the setup into VIBRANCE-2 where we see potential for high efficacy and good tolerability, and with the base business performing well, and a new growth driver added, we would be buyers at these levels; price target to $47.X on model updates as we integrate AVDL.
0 · Reply
NebulaKnight65
NebulaKnight65 Oct. 22 at 1:03 PM
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 22 at 12:50 PM
$AVDL (+3.7% pre) Avadel settles with $JAZZ Jazz Pharma; agrees to be acquired by $ALKS Alkermes https://ooc.bz/l/81384
0 · Reply
notreload_ai
notreload_ai Oct. 22 at 12:07 PM
$ALKS , $AVDL ... Alkermes announces $2.1B acquisition of Avadel Pharmaceuticals to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026. https://notreload.xyz/alkermes-acquires-avadel-sleep-drug-deal/
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 22 at 12:05 PM
Avadel Stock Rises After Acquisition Offer By Alkermes $ALKS $AVDL https://stocktwits.com/news/equity/markets/avadel-stock-rises-after-acquisition-offer-by-alkermes/cLG57nXR3q3
0 · Reply
G101SPM
G101SPM Oct. 22 at 12:03 PM
$AVDL $18.50 bid. DAC (dollar average cost includes 6-trnascation to reduce net cost to $8.98 with last trade at 7.61 (2.28.25). UPDATE: Avadel Pharmaceuticals: Alkermes (ALKS) and Avadel Pharmaceuticals announces that the companies entered into definitive agreement under which Alkermes will acquire Avadel for total transaction consideration of up to $20.00 per share in cash. ^^^ Alkermes ($ALKS) and Avadel Pharmaceuticals ($AVDL) announce that the companies have entered into a definitive agreement under which Alkermes will acquire Avadel, a commercial-stage biopharmaceutical company, for total transaction consideration of up to $20.00 per share in cash, which values Avadel at approximately $2.1 billion and represents a premium of 38% to the weighted average trading price of Avadel over the three months prior to today's announcement and a premium of 12% to Avadel's closing price on Oct. 21, 2025 (being the last business day prior to publication of this announcement). The transaction has been approved by the boards of directors of both companies and is expected to close in the first quarter of 2026. The planned acquisition adds Avadel's FDA-approved product, LUMRYZ (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in patients over 7 years of age with narcolepsy, to Alkermes' commercial portfolio. This strategic move accelerates Alkermes' entry into the sleep medicine market and enhances its ability to unlock the full potential of its late-stage development pipeline focused on central disorders of hypersomnolence. The transaction is expected to be immediately accretive upon closing and represents a compelling financial and strategic opportunity, leveraging Alkermes' existing commercial expertise and operational infrastructure and adding new capabilities in rare disease. With net revenues of $265 -- $275 million expected in 2025 and an estimated population of >50,000 oxybate-eligible narcolepsy patients in the United States, LUMRYZ™ has been on a robust growth trajectory, with significant opportunity for growth ahead. Alkermes expects to finance the acquisition with cash on hand, supplemented by the issuance of new debt. The transaction, which has been approved by the boards of directors of both Alkermes and Avadel, is expected to close in the first quarter of 2026, subject to the Conditions set out in Appendix III of this Announcement, including certain regulatory approvals and approvals by Avadel's shareholders.
1 · Reply
notreload_ai
notreload_ai Oct. 22 at 11:57 AM
BREAKING: $ALKS enters sleep medicine market with $2.1B $AVDL deal.
0 · Reply
SenefAS
SenefAS Oct. 22 at 11:21 AM
$ALKS to acquire $AVDL for $18.50/share in Cash + CVR Who’s next ? $MCRB
0 · Reply
Quantumup
Quantumup Oct. 15 at 11:16 AM
UBS⬇️ $HRMY's PT to $43 from $50/⬇️'29 sales ests to $1.08B from $1.34B on Wakix competitive pressures in the NT1/NT2 mkt from pot'l orexin agonists launch. $TAK $ALKS $CNTA ESALY NLSP JAZZ AXSM AVDL UBS said in its note to investors: Based on our buy-side conversations, investors are concerned as HRMY's opportunity to grow into a multi-asset company dwindled with the recent Zygel Ph3 FXS failure (and IH approval rejection). Moreover, it is likely that HRMY's base business Wakix will face competitive pressure in the narcolepsy market with potential orexin agonists launch. We lower our PT to $43 (from $50) based on an unchanged 2.75x multiple on lower 2029E sales of $1.08BN (from $1.34BN) due to the potential competition on Wakix sales and zeroed out Zygel sales. Our PT is supported by DCF.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 13 at 6:55 PM
0 · Reply
BOOGEYMAN_TRADEZ
BOOGEYMAN_TRADEZ Oct. 13 at 4:59 PM
$ATYR Some pretty stunning DD here for our $ATYR swing IMO.. (approx 40% short) maybe the next $SAVA bounce Director (Paul Schimmel) who just bought 1,000,000 shares of $ATYR at .90-.95 range also founded the following $RGEN up 1,356% all time $ALNY up 7,748% all time $ALKS up 539% all time $CBST bought for 8.4 billion by Merck Angiosyn bought by Pfizer in 2005
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 9 at 2:16 PM
List 9/26/25 $ALC $ALE $ALKS $ALLE 🔥 Cycle Trading Signal plugged into AI 🔥
1 · Reply
Quantumup
Quantumup Oct. 8 at 11:59 AM
Mizuho reiterated $ALKS Outperform/$40 $CNTA $AXSM $TAK Mizuho said in its note: We preview 3Q25 for ALKS and expect slightly above-consensus 3Q25 revenues of $358M (vs. $355M Bloomberg cons) and GAAP EPS of $0.31 (vs. $0.30 cons), driven by potentially above-consensus Aristada and Lybalvi sales. That said, we believe investors are likely more focused on the Vibance-2 Phase 2 readout for alixorexton (ALKS-2680) in narcolepsy type 2 (NT2) this fall. Heading into this readout, we believe the key concerns are potential for high visual AE rates as Vibrance-2 evaluates higher doses (10, 14, 18mg) than 8mg, which demonstrated a significantly higher-than-expected visual AE rate of 29% in the Vibrance-1 NT1 trial. These concerns may be overstated, as NT2/IH patients are likely less hypersensitive to orexin than NT1, and so the visual AE rates may not be as high. Thus, the risk/reward could be skewed to the upside. Maintain $40 PT and OP rating.
0 · Reply
Quantumup
Quantumup Oct. 6 at 2:06 PM
Piper Sandler reit'd $ALKS OW-$38 and said: We caught up with Alkermes senior management as part of investor meetings that we hosted in Europe. $CNTA $AXSM $JAZZ $AVDL As we move closer to results from the Phase II Vibrance-2 study in narcolepsy type 2 (NT2) for orexin 2 receptor (OX2R) agonist alixorexton sometime in November (per management expectations), we provide herein a few brief thoughts on what we believe would count as a "win" from the trial. We continue to believe that the underlying size of the treated narcolepsy (narcolepsy type 1 (NT1) and NT2 combined) and idiopathic hypersomnia (IH) populations translates into ample room for a handful of novel OX2R agonists to readily coexist. Beyond that, opportunities for the category beyond sleep/wake are very much under the broader investor radar, though we would keep in mind that visibility into these opportunities (e.g., psychiatric indications) should improve over the next 12-18 months. We reiterate our Overweight rating and $38 PT.
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:16 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:06 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply